Old drug, new hope: lenalidomide takes on rare histiocyte disorders
NCT ID NCT02523040
First seen Jan 04, 2026 · Last updated May 15, 2026 · Updated 21 times
Summary
This study tests the chemotherapy drug lenalidomide in 12 adults with one of three rare diseases where immune cells grow out of control: Langerhans cell histiocytosis, Erdheim-Chester disease, or histiocytic sarcoma. The main goal is to see how many people have their disease shrink or disappear. This is a phase 2 trial, meaning the drug is already known to be safe, and researchers are checking how well it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LANGERHANS CELL HISTIOCYTOSIS (LCH) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.